WO2002053587A3 - Polypeptide induisant des anticorps neutralisant le vih - Google Patents

Polypeptide induisant des anticorps neutralisant le vih Download PDF

Info

Publication number
WO2002053587A3
WO2002053587A3 PCT/FR2002/000031 FR0200031W WO02053587A3 WO 2002053587 A3 WO2002053587 A3 WO 2002053587A3 FR 0200031 W FR0200031 W FR 0200031W WO 02053587 A3 WO02053587 A3 WO 02053587A3
Authority
WO
WIPO (PCT)
Prior art keywords
neutralising antibodies
inducing hiv
polypeptide inducing
polypeptide
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2002/000031
Other languages
English (en)
Other versions
WO2002053587A2 (fr
Inventor
Robert Brasseur
Benoit Charloteaux
Michel Chevalier
Habib Raphaelle El
Tino Krell
Regis Sodoyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0100141A external-priority patent/FR2819256B1/fr
Application filed by Aventis Pasteur SA filed Critical Aventis Pasteur SA
Priority to DE60210936T priority Critical patent/DE60210936T2/de
Priority to AU2002229850A priority patent/AU2002229850A1/en
Priority to CA2431881A priority patent/CA2431881C/fr
Priority to EP02710945A priority patent/EP1368478B1/fr
Publication of WO2002053587A2 publication Critical patent/WO2002053587A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002053587A3 publication Critical patent/WO2002053587A3/fr
Priority to CY20061100881T priority patent/CY1105629T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un polypeptide capable de former une structure correspondant à ou mimant l'état intermédiaire de la gp41 ainsi que son utilisation dans un vaccin utilisation dans la prévention et le traitement des infections par le VIH.
PCT/FR2002/000031 2001-01-05 2002-01-04 Polypeptide induisant des anticorps neutralisant le vih Ceased WO2002053587A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE60210936T DE60210936T2 (de) 2001-01-05 2002-01-04 Polypeptid, das neutralisierende antikörper gegen hiv induziert
AU2002229850A AU2002229850A1 (en) 2001-01-05 2002-01-04 Polypeptide inducing hiv-neutralising antibodies
CA2431881A CA2431881C (fr) 2001-01-05 2002-01-04 Polypeptide induisant des anticorps neutralisant le vih
EP02710945A EP1368478B1 (fr) 2001-01-05 2002-01-04 Polypeptide induisant des anticorps neutralisant le vih
CY20061100881T CY1105629T1 (el) 2001-01-05 2006-06-28 Πολυπεπτιδιο που επαγει αντισωματα εξουδετερωσης του ηιv

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR01/00141 2001-01-05
FR0100141A FR2819256B1 (fr) 2001-01-05 2001-01-05 Polypeptide induisant des anticorps neutralisant le vih
FR0100848 2001-01-23
FR01/00848 2001-01-23

Publications (2)

Publication Number Publication Date
WO2002053587A2 WO2002053587A2 (fr) 2002-07-11
WO2002053587A3 true WO2002053587A3 (fr) 2003-09-25

Family

ID=26212817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/000031 Ceased WO2002053587A2 (fr) 2001-01-05 2002-01-04 Polypeptide induisant des anticorps neutralisant le vih

Country Status (10)

Country Link
EP (1) EP1368478B1 (fr)
AT (1) ATE324450T1 (fr)
AU (1) AU2002229850A1 (fr)
CA (1) CA2431881C (fr)
CY (1) CY1105629T1 (fr)
DE (1) DE60210936T2 (fr)
DK (1) DK1368478T3 (fr)
ES (1) ES2260416T3 (fr)
PT (1) PT1368478E (fr)
WO (1) WO2002053587A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364744B2 (en) 2003-04-11 2008-04-29 Institut Pasteur Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1445614A1 (fr) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Méthodes d'évaluation in vitro de l'état de progression d'un virus HIV chez un individu
CN1954217B (zh) * 2004-02-06 2013-05-08 国立健康与医学研究所 衍生自gp41的多肽、含有所述多肽的疫苗组合物以及用于治疗个体HIV病毒感染的用途
WO2014020205A2 (fr) * 2012-07-31 2014-02-06 Universidad De Granada Immunogènes anti-vih améliorés
CN114605505B9 (zh) * 2018-08-09 2025-04-29 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000008043A2 (fr) * 1998-08-03 2000-02-17 The University Of Montana Prevention et traitement de pathologie virale
WO2000040616A1 (fr) * 1999-01-08 2000-07-13 Panacos Pharmaceuticals, Inc. TECHNIQUES D'ELICITATION D'ANTICORPS NEUTRALISANTS CIBLANT gp41 DU VIH-1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000008043A2 (fr) * 1998-08-03 2000-02-17 The University Of Montana Prevention et traitement de pathologie virale
WO2000040616A1 (fr) * 1999-01-08 2000-07-13 Panacos Pharmaceuticals, Inc. TECHNIQUES D'ELICITATION D'ANTICORPS NEUTRALISANTS CIBLANT gp41 DU VIH-1

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CAO J. ET AL.: "Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein.", JOURNAL OF VIROLOGY, vol. 67, no. 5, 1993, pages 2747 - 2755, XP001030658, ISSN: 0022-538X *
LACASSE R. ET AL.: "Fusion-competent vaccines: Broad neutralization of primary isolates of HIV", SCIENCE, vol. 283, no. 5400, 15 January 1999 (1999-01-15), pages 357 - 362, XP002120812, ISSN: 0036-8075 *
MALASHKEVICH V. N. ET AL.: "Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: Conserved helical interactions underlie the broad inhibitory activity of gp41 peptides", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, no. 16, 4 August 1998 (1998-08-04), pages 9134 - 9139, XP002170630, ISSN: 0027-8424 *
MONTEFIORI D. ET AL.: "Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 15, no. 8, 20 May 1999 (1999-05-20), pages 689 - 698, XP002144409, ISSN: 0889-2229 *
WEISSENHORN W. ET AL.: "ATOMIC STRUCTURE OF THE ECTODOMAIN FROM HIV-1 GP41", NATURE, vol. 387, no. 6631, 22 May 1997 (1997-05-22), pages 426 - 430, XP001002849, ISSN: 0028-0836 *
WENG Y. ET AL.: "Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41.", JOURNAL OF VIROLOGY, vol. 72, no. 12, December 1998 (1998-12-01), pages 9676 - 9682, XP002180284, ISSN: 0022-538X *
WENG Y. ET AL.: "Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41.", JOURNAL OF VIROLOGY, vol. 74, no. 11, June 2000 (2000-06-01), pages 5368 - 5372, XP002218221, ISSN: 0022-538X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364744B2 (en) 2003-04-11 2008-04-29 Institut Pasteur Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV

Also Published As

Publication number Publication date
CY1105629T1 (el) 2010-12-22
EP1368478B1 (fr) 2006-04-26
DE60210936T2 (de) 2006-10-19
DK1368478T3 (da) 2006-08-28
DE60210936D1 (de) 2006-06-01
WO2002053587A2 (fr) 2002-07-11
EP1368478A2 (fr) 2003-12-10
AU2002229850A1 (en) 2002-07-16
PT1368478E (pt) 2006-07-31
CA2431881A1 (fr) 2002-07-11
ATE324450T1 (de) 2006-05-15
ES2260416T3 (es) 2006-11-01
CA2431881C (fr) 2011-02-22

Similar Documents

Publication Publication Date Title
WO2001034801A3 (fr) Vaccins contenant de la gelatine recombinante
WO2003039470A3 (fr) Immunogene polyvalent
BR0014282A (pt) Vacinas
AU2002340167A1 (en) Anti-hla-dr antibodies and the methods of using thereof
AU2002365228A1 (en) Antigen panels and methods of using the same
AU2002354009A1 (en) Process for the preparation of secondary and tertiary amino-functional silanes, iminoorganosilanes and/or imidoorganosilanes
WO2001040473A3 (fr) Antigenes de pseudomonas aeruginosa
AU2002233424A1 (en) Peptides having affinity for the GP120 viral protein and use thereof
WO2002044384A3 (fr) Epitopes lymphocytaires t des proteines l1 et e7 de papillomavirus et leur utilisation a des fins de diagnostic et de therapie
AU2002229850A1 (en) Polypeptide inducing hiv-neutralising antibodies
AU2002213882A1 (en) Attenuated hiv strains and use thereof
AU2002337843A1 (en) Processes for the preparation of substituted isoxazoles and 2-isoxazolines
AU2001294786A1 (en) Use of il-8 protein modulators in the treatment of viral infections
GB0217548D0 (en) Four human zinc-finger-containing proteins:MDZ3.MDZ4,MDZ7 and MDZ12
AU2001276258A1 (en) Ceramic component and the use thereof
AU5565401A (en) Materials and methods for the treatment of depression
AU2001261534A1 (en) The meca-79 antigen and related methods
AU2002330245A1 (en) Isolated polypeptides and compositions from the venom of p. transvaalicus and methods of use
HUP0303423A3 (en) Natural antibody active against hiv virus
AU2002338856A1 (en) Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination against sag
AU2002241162A1 (en) Intimins in the prevention or treatment of infections:ii
AU2003255866A1 (en) Gp41 epitope and uses thereof for the treatment of hiv infections
AU2002321852A1 (en) Recombinant polypeptide for immunocastration and vaccine comprising the same
FR2819256B1 (fr) Polypeptide induisant des anticorps neutralisant le vih
AU2002311968A1 (en) Antibodies and antigens of hiv viremia controllers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2431881

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002710945

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002710945

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWG Wipo information: grant in national office

Ref document number: 2002710945

Country of ref document: EP